Identifying the Minimum Volume Threshold for Retroperitoneal Soft Tissue Sarcoma Resection: Merging National Data with Consensus Expert Opinion.

MedStar author(s):
Citation: Journal of the American College of Surgeons. 230(1):151-160.e2, 2020 01.PMID: 31672672Institution: MedStar Health Research Institute | MedStar Washington Hospital CenterDepartment: Surgery/General SurgeryForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Retroperitoneal Neoplasms/pa [Pathology] | *Retroperitoneal Neoplasms/su [Surgery] | *Sarcoma/pa [Pathology] | *Sarcoma/su [Surgery] | *Soft Tissue Neoplasms/pa [Pathology] | *Soft Tissue Neoplasms/su [Surgery] | Aged | Consensus | Databases, Factual | Expert Testimony | Female | Humans | Male | Middle Aged | Retrospective Studies | Tumor BurdenYear: 2020Local holdings: Available online from MWHC library: 1997 - present, Available in print through MWHC library:1999-2007ISSN:
  • 1072-7515
Name of journal: Journal of the American College of SurgeonsAbstract: BACKGROUND: The complexity of retroperitoneal soft tissue sarcoma (RPS) surgery has prompted international recommendations to regionalize it to high-volume hospitals (HVH's). A minimum procedural volume threshold for RPS is not yet defined, hampering effective referral and regionalization in the US. This multi-hospital study sought to establish a HVH threshold informed by national data and international expert opinion.CONCLUSIONS: This is the first multicenter analysis to merge data-driven RPS surgery volume thresholds to clinically meaningful sarcoma expert opinions. These findings will help inform national/international consensus recommendations, a practical volume threshold, trial design, and motivate evidence-based hospital referral. Copyright (c) 2019. Published by Elsevier Inc.RESULTS: Overall mortality risk was reduced by 4% per additional case (HR 0.96, 95% CI 0.95-0.98) up to a threshold of 13 cases/year; no further reduction was observed over 13 (HR 0.99, 95% CI 0.97-1.01). After revealing the results from our statistical analysis, 71.4% of respondents who initially chose >30 cases/year as a cutoff shifted their response to a lower value. Over 56% cited 11-20 procedures/year as the cutoff for a HVH. Median survival in hospitals with <13 vs. >13 cases/year was 94 vs. 139 months (p<0.001). 40% of respondents cited 1-2% as an acceptable 90-day mortality. This was achieved with a minimum of 13 cases/year based on risk-adjusted survival analysis.STUDY DESIGN: The 2004-2015 National Cancer Database identified 8,721 surgically treated RPS patients. Multivariable models, utilizing linear splines, identified annual volume thresholds predictive of overall and 90-day mortality. Transatlantic Australasian Retroperitoneal Soft Tissue Sarcoma Working Group members (n=48) completed a 15-item survey regarding this data.All authors: Al-Refaie WB, Chan KS, Shara N, Villano AM, Zeymo AOriginally published: Journal of the American College of Surgeons. 2019 Oct 11Fiscal year: FY2020Digital Object Identifier: Date added to catalog: 2019-11-19
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 31672672 Available 31672672

Available online from MWHC library: 1997 - present, Available in print through MWHC library:1999-2007

BACKGROUND: The complexity of retroperitoneal soft tissue sarcoma (RPS) surgery has prompted international recommendations to regionalize it to high-volume hospitals (HVH's). A minimum procedural volume threshold for RPS is not yet defined, hampering effective referral and regionalization in the US. This multi-hospital study sought to establish a HVH threshold informed by national data and international expert opinion.

CONCLUSIONS: This is the first multicenter analysis to merge data-driven RPS surgery volume thresholds to clinically meaningful sarcoma expert opinions. These findings will help inform national/international consensus recommendations, a practical volume threshold, trial design, and motivate evidence-based hospital referral. Copyright (c) 2019. Published by Elsevier Inc.

RESULTS: Overall mortality risk was reduced by 4% per additional case (HR 0.96, 95% CI 0.95-0.98) up to a threshold of 13 cases/year; no further reduction was observed over 13 (HR 0.99, 95% CI 0.97-1.01). After revealing the results from our statistical analysis, 71.4% of respondents who initially chose >30 cases/year as a cutoff shifted their response to a lower value. Over 56% cited 11-20 procedures/year as the cutoff for a HVH. Median survival in hospitals with <13 vs. >13 cases/year was 94 vs. 139 months (p<0.001). 40% of respondents cited 1-2% as an acceptable 90-day mortality. This was achieved with a minimum of 13 cases/year based on risk-adjusted survival analysis.

STUDY DESIGN: The 2004-2015 National Cancer Database identified 8,721 surgically treated RPS patients. Multivariable models, utilizing linear splines, identified annual volume thresholds predictive of overall and 90-day mortality. Transatlantic Australasian Retroperitoneal Soft Tissue Sarcoma Working Group members (n=48) completed a 15-item survey regarding this data.

English

Powered by Koha